BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33889952)

  • 21. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
    D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
    Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
    [No Abstract]   [Full Text] [Related]  

  • 23. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
    Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
    Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
    Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
    Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
    Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
    Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.
    Suntsova EV; Demina IM; Ignatova AA; Ershov NM; Trubina NM; Dobrynina J; Serkova IV; Supik ZS; Orekhova EV; Hachatryan LA; Kotskaya NN; Pshonkin AV; Maschan AA; Novichkova GA; Panteleev MA
    Int J Hematol; 2017 Jun; 105(6):841-848. PubMed ID: 28271416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
    Meyer O; Salama A
    Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 32. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
    Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
    [No Abstract]   [Full Text] [Related]  

  • 33. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C
    Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154
    [No Abstract]   [Full Text] [Related]  

  • 34. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists.
    Forsythe A; Schneider J; Pham T; Bhor M; Said Q; Allepuz A; Socorro O Portella MD; Kwon CS; Roy AN
    J Comp Eff Res; 2020 May; 9(7):447-457. PubMed ID: 32175766
    [No Abstract]   [Full Text] [Related]  

  • 38. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
    Gudbrandsdottir S; Frederiksen H; Hasselbalch H
    Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
    Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
    Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
    N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.